Chronic constipation: from pathophysiology to management

Minerva Gastroenterol (Torino). 2023 Jun;69(2):277-290. doi: 10.23736/S2724-5985.22.03335-6. Epub 2023 Feb 2.

Abstract

Chronic constipation (CC) is one of the most common conditions found in gastrointestinal clinical practice and defined by the presence of fewer than 3 bowel movements per week and/or more than one fourth of bowel movements with Bristol stool form types 1 or 2. CC affects people regardless of race, age, or sex, although it is most common in women and in elderly. It is associated with relevant disease burden, including significant impairment of patients' quality of life. In the absence of alarm features, patients should receive a symptom-based diagnosis. Treatment options include lifestyle and general measures, bulking agents, in particular dietary fiber supplementation. Osmotic laxatives are currently considered the first-line gold-standard pharmacological treatment of CC together with stimulant laxatives which are often used as a rescue therapy. When necessary, prokinetic agents and/or intestinal secretagogues can be used. Biofeedback may be indicated in patients with functional defecation disorders. In this review, we will briefly summarize the current understanding on epidemiology, classification, pathophysiology and clinical evaluation of CC and discuss in depth the pharmacological and not pharmacological management of patients with this disorder.

Publication types

  • Review

MeSH terms

  • Aged
  • Constipation / diagnosis
  • Constipation / etiology
  • Constipation / therapy
  • Female
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Intestines
  • Laxatives* / therapeutic use
  • Quality of Life*

Substances

  • Laxatives
  • Gastrointestinal Agents